Aqupla (nedaplatin) / Simcere - LARVOL DELTA

Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial. (PubMed, JAMA Oncol) - P2 | "Patients were randomly assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2, and platinum [cisplatin, 75 mg/m2; carboplatin, area under the curve, 5; or nedaplatin, 100 mg/m2]) or chemotherapy alone, followed by surgery after 4 to 6 weeks. This randomized clinical trial found that among patients with resectable stage IIIA or IIIB (T3N2) NSCLC, camrelizumab plus chemotherapy, compared with chemotherapy alone, significantly improved the pCR rate with manageable toxic effects. ClinicalTrials.gov Identifier: NCT04338620."

Clinical • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Patient Characteristics, Treatment Patterns, and Safety of 1L Osimertinib+Ctx in EGFRm NSCLC: A Prospective, Real-World Study (IASLC-WCLC 2026) - "At the time of DCO (30 November 2025), with a median follow-up duration of 9.1 months (IQR: 5.97, 12.16), Two distinct types of CTx administered in combination with osimertinib were observed, a total of 429 (80.6%) patients received induction therapy, with a median duration of induction CTx of 3.0 months (IQR: 2.2, 3.9), 397(92.5% ) were treated with cisplatin/carboplatin-based CTx regimens plus pemetrexed, and 21(4.9%) received lobaplatin/nedaplatin plus pemetrexed, 246 out of these 429 patients received maintenance CTx, of which 242(98.4%) was pemetrexed. In parallel, a total of 103 (19.4%) patients received only Single-agent CTx regimens including 61 patients of pemetrexed, 34 patients of etoposide, and 8 patients of vinorelbine.The most common TRAE was anemia(51.1%) and Leukopenia(49.7%), and no new safety signals were identified...CTx regimens were diverse in clinical practice; however, the majority consisted of cisplatin/carboplatin plus pemetrexed, no new AEs were..."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Leukopenia • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR

Postoperative Adjuvant therapy versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. (PubMed, Oncologist) - "The results of this phase III study indicated that PORT/POCRT could significantly improve DFS and OS in stage IIB-III esophageal squamous cell carcinoma compared with surgery alone with acceptable toxicities. In-field and out-of-field recurrences were comparable between the POCRT and PORT groups, which demonstrates the rationality and safety of the radiation field used in our study. The postoperative regimens in this trial might be accepted as a standard treatment options for pathological stage IIB-III esophageal cancer. Larger sample size prospective randomized trials to identify the value are warranted."

Clinical • Journal • P3 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology • Squamous Cell Carcinoma

Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial. (PubMed, EClinicalMedicine) - P2 | "Patients received neoadjuvant therapy comprised of albumin-bound paclitaxel, nedaplatin and toripalimab every 3 weeks, for 2 cycles, followed by CCRT (total dose 60Gy in cohort A, 50Gy in cohort B, combined with oral capecitabine). Further investigation is warranted. None."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Pneumonia • Squamous Cell Carcinoma

Clinical activity of platinum rechallenge with nedaplatin plus irinotecan in recurrent cervical cancer following prior platinum-based systemic chemotherapy: a single-center retrospective study. (PubMed, Int J Clin Oncol) - "Nedaplatin plus irinotecan demonstrated clinically meaningful activity with manageable toxicity in selected patients with recurrent cervical cancer following prior platinum-based systemic chemotherapy. Platinum rechallenge may be a potential treatment option in this setting, although further studies are warranted to identify patients most likely to benefit."

Journal • Retrospective data • Cervical Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia

Spheroid cultures reveal cancer stem cell enrichment and distinct chemotherapeutic response in triple-negative breast cancer. (PubMed, BMC Cancer) - "Taken together, these findings highlight molecular and cellular determinants of spheroid formation in breast cancer cell lines, including stemness-associated features and upregulation of TENM4. Our results further demonstrate that intrinsic tumor subtype shapes spheroid morphology, transcriptional profiles, and drug response, providing novel insight into the mechanisms underlying 3D growth and chemoresistance that may help inform future therapeutic strategies."

Journal • Brain Cancer • Breast Cancer • Glioblastoma • Melanoma • Oncology • Solid Tumor • Triple Negative Breast Cancer • CNPY2 • TENM4

A phase II randomized trial comparing radiation doses in concurrent chemoradiotherapy with TS-1/nedaplatin for curative treatment of newly diagnosed or recurrent esophageal cancer. (PubMed, Int J Radiat Oncol Biol Phys) - "A radiation dose of 50.4 Gy remains the standard dose in concurrent CRT for esophageal squamous cell carcinoma."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study. (PubMed, J Immunother Cancer) - P2 | "This exploratory study demonstrated preliminary efficacy and larynx preservation with manageable toxicity, possibly supporting further evaluation of induction toripalimab plus chemotherapy sequential cCRT with nimotuzumab, followed by toripalimab maintenance in stage IVB HSCC. Peripheral lymphocytes may warrant further investigation as candidate biomarkers in locally advanced disease."

IO biomarker • Journal • P2 data • Tumor mutational burden • Head and Neck Cancer • Hypopharyngeal Cancer • Mucositis • Oncology • Solid Tumor • Squamous Cell Carcinoma • CD8 • EGFR • PD-L1 • TMB

Neoadjuvant Therapy with Nimotuzumab Combined with Immunotherapy and Chemotherapy for Early-Stage Laryngeal/Hypopharyngeal Squamous Cell Carcinoma:A Single-Arm, Prospective, Exploratory Clinical Study (ChiCTR) - P2 | N=24 | Recruiting | Sponsor: The Second People's Hospital of Shandong Province; The Second People's Hospital of Shandong Province Input only one institution

New P2 trial • Head and Neck Cancer • Hypopharyngeal Cancer • Laryngeal Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: a single-arm phase II clinical trial. (PubMed, Future Oncol) - P2 | "Locally advanced ESCC patients received two cycles of nedaplatin plus paclitaxel or albumin-bound paclitaxel with concurrent radiotherapy (41.4-50.4 Gy) as neoadjuvant treatment. Clinical trial registration: Chinese Clinical Trial Registry (http://www.chictr.org.cn), identifier is ChiCTR1900024628. Date of registration: 19 July 2019."

IO biomarker • Journal • P2 data • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • FOXP3 • TIGIT

Preoperative neoadjuvant chemotherapy was associated with improved local control in selected cases of locally advanced or invasive oral squamous cell carcinoma: a retrospective single-center study. (PubMed, Oral Maxillofac Surg) - "In this retrospective single-center cohort, NAC administered before curative surgery was associated with improved local control in selected patients with advanced OSCC, particularly those with T4 tumors or high-grade histological invasion (Yamamoto-Kohama grade 4). However, this association did not translate into a significant overall survival benefit. The findings should be interpreted as hypothesis-generating given the observational design and substantial baseline imbalances between groups, and prospective validation is required before clinical recommendations can be made."

Journal • Retrospective data • Oncology • Oral Cancer • Squamous Cell Carcinoma

Recurrence after Long-Term Use of Poly ADP-Ribose Polymerase Inhibitors Triggered by Therapy-Related Myeloid Neoplasms: A Case Report. (PubMed, Case Rep Oncol) - "At the time of her sixth relapse, she received five cycles of nedaplatin and was subsequently administered olaparib...She received eight cycles of venetoclax and azacitidine for approximately 1 year following her diagnosis of acute myeloid leukemia, but no hematologic response was achieved...She was eventually transferred to a hospice program, where she died from ovarian cancer and acute myeloid leukemia. While long-term PARP inhibitor therapy may prolong survival in ovarian cancer, this case highlights the risk of therapy-related myeloid neoplasms, particularly in heavily pretreated patients, and underscores the need for careful long-term monitoring and consideration of optimal maintenance duration."

Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • High Grade Serous Ovarian Cancer • Leukemia • Myelodysplastic Syndrome • Oncology • Ovarian Cancer • Solid Tumor

Ivonescimab monotherapy in an elderly patient with EGFR-TKI-resistant advanced lung adenocarcinoma and pericardial effusion: a case report and literature review. (PubMed, Front Immunol) - "Disease progression was observed after four cycles of chemotherapy (docetaxel plus nedaplatin) and subsequent EGFR-TKI therapy (icotinib and later furmonertinib combined with anlotinib). This case suggests that ivonescimab monotherapy can achieve disease control with an acceptable safety profile in an elderly, heavily pretreated NSCLC patient with EGFR-TKI resistance and malignant pericardial effusion. It may represent a viable treatment option for this challenging population."

IO biomarker • Journal • Monotherapy • Review • Cardiovascular • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Solid Tumor • GRP-10

Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non-Small Cell Lung Cancer. (PubMed, Cancer Sci) - "The primary endpoint was treatment tolerability, defined as completion of the planned four cycles, and compared with historical data for the standard cisplatin plus vinorelbine regimen. These results indicate that adjuvant chemotherapy with nedaplatin plus docetaxel is tolerable and effective in patients with completely resected NSCLC. Trial Registration: UMIN number: 000004634."

Journal • Anorexia • Hematological Disorders • Lung Cancer • Nephrology • Neutropenia • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor

CCL3+ neutrophil signature as a predictor of response to neoadjuvant toripalimab plus chemotherapy in hypopharyngeal squamous cell carcinoma: A phase II trial. (ASCO 2026) - P=N/A | " In this prospective, single-center, single-arm phase II trial, patients with resectable locally advanced HPSCC received two cycles of neoadjuvant toripalimab, albumin-bound paclitaxel, and nedaplatin. The efficacy of nCIT in HPSCC is predetermined by a baseline immune architecture orchestrated by a CCL3+ neutrophil subset. The Neu_CCL3 gene signature is a promising, clinically translatable biomarker that can fill a critical gap in precision immunotherapy for HPSCC."

Clinical • IO biomarker • P2 data • Hypopharyngeal Cancer • Oncology • Squamous Cell Carcinoma • CCL3 • PD-L1

Fruquintinib in combination with camrelizumab, paclitaxel liposome, and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from a single-arm, phase II study. (ASCO 2026) - P1/2 | "The combination of fruquintinib, camrelizumab, paclitaxel liposome, and nedaplatin demonstrated encouraging anti-tumor activity with a manageable toxicity profile as a first-line treatment for advanced ESCC, warranting further investigation in larger, randomized studies."

Clinical • Combination therapy • Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Squamous Cell Carcinoma

Efficacy and safety of schedule-modified oral capecitabine/S-1 as maintenance therapy for stage N3 nasopharyngeal carcinoma after definitive chemoradiotherapy: a multicentre, single-arm phase II clinical trial. (PubMed, BMC Oral Health) - P2 | "Schedule-modified oral maintenance chemotherapy with capecitabine or S-1 following definitive chemoradiotherapy showed promising efficacy and manageable toxicity in stage N3 NPC, supporting further investigation of this consolidation approach."

Journal • P2 data • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Solid-variant primary pulmonary adenoid cystic carcinoma with pleural metastasis and malignant pleural effusion: a rare case report. (PubMed, Front Oncol) - "Given the advanced stage, the patient received a systemic combination of tislelizumab, cyclophosphamide, pegylated liposomal doxorubicin, and nedaplatin, initially combined with local intrapleural therapy. This case highlights a diagnostic pitfall in lung tumors exhibiting squamoid immunophenotypes and underscores the necessity of incorporating myoepithelial markers into the diagnostic workup. Furthermore, it provides a cautiously interpreted clinical observation of immune checkpoint inhibitor-based combination therapy in advanced PACC."

IO biomarker • Journal • Pleural effusion • Adenoid Cystic Carcinoma • Lung Cancer • Oncology • Respiratory Diseases • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • SOX10 • TP63

Clinical Study on Cervical Cancer: Spatial Segmentation Brachytherapy-Induced Immunotherapy Combined with Radical Concurrent Chemoradiotherapy (ChiCTR) - P=N/A | N=15 | Sponsor: Linfen Central Hospital; Linfen Central Hospital

IO biomarker • New trial • Cervical Cancer • Oncology • Solid Tumor

Primary thoracic synovial sarcoma in a 45-year-old male: A case report and literature review. (PubMed, Oncol Lett) - "The patient underwent surgical resection of the tumor followed by adjuvant chemotherapy with doxorubicin and nedaplatin. Regrettably, the patient showed widespread metastatic progression 8 months post-surgery and died 18 months thereafter because of tumor dissemination and associated complications. This case highlights the diagnostic challenges of PTSS and underscores the need for increased clinical awareness of rare thoracic tumors."

Journal • Chronic Cough • Cough • Oncology • Pulmonary Disease • Respiratory Diseases • Sarcoma • Solid Tumor • Synovial Sarcoma • Thoracic Cancer

Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study. (PubMed, J Cancer Res Clin Oncol) - "This chemotherapy regimen demonstrated satisfactory therapeutic efficacy and manageable toxicity in heavily pretreated PROC, suggesting its potential as a viable treatment alternative."

Journal • Platinum resistant • Retrospective data • Epithelial Ovarian Cancer • Hematological Disorders • Oncology • Ovarian Cancer • Solid Tumor

Prognostic Impact of Carboplatin-Paclitaxel versus Nedaplatin-Paclitaxel in Advanced Epithelial Ovarian Cancer- A real world Study from Single Cancer Center (SGO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel Compared to Docetaxel Plus Nedaplatin as Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis. (PubMed, Cancer Manag Res) - "The NP regimen demonstrated comparable long-term survival outcomes to the TP regimen as IC for LA NPC, with a distinct toxicity profile. NP may serve as a valuable alternative, offering a favorable hematological toxicity profile and eliminating the need for corticosteroid premedication, albeit with a higher incidence of low-grade neurotoxicity and myalgia."

Journal • Hematological Disorders • Musculoskeletal Pain • Nasopharyngeal Carcinoma • Neutropenia • Oncology • Pain • Solid Tumor

CCL3+ neutrophil signature predicts response to neoadjuvant toripalimab plus chemotherapy in patients with hypopharyngeal squamous cell carcinoma: A phase II trial. (PubMed, Clin Cancer Res) - "The efficacy of nCIT in HPSCC is predetermined by a baseline immune architecture orchestrated by a CCL3+ neutrophil subset. The Neu_CCL3 gene signature is a promising, clinically translatable biomarker that can fill a critical gap in precision immunotherapy for HPSCC."

IO biomarker • Journal • P2 data • Hypopharyngeal Cancer • Oncology • Squamous Cell Carcinoma • CCL3 • PD-L1

Nedaplatin induced QT prolongation with polymorphic ventricular tachyarrhythmia: clinical experience and review of literature. (PubMed, Cardiooncology) - No abstract available

Journal • Cardiovascular • Ventricular Tachycardia